Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research C...(opportunity for Kendle said President S...)

Date:6/2/2008

opportunity for Kendle," said President Simon Higginbotham. "The addition of DecisionLine is an important step in building Kendle's global capabilities for exploration of early phase drug candidates and supports our strategic initiative to drive growth in our Phase I business. We look forward to leveraging the benefits of our combined and strengthened scientific expertise as we assist our customers in tapping their most promising new compounds for development."

DecisionLine was founded in 1997 by President and CEO Edward M. Sellers, MD, PhD, FRCPC, FACP and Senior Vice President, Research Development & Medical Affairs Myroslava K. Romach, MSc, MD, FRCPC. The company's 82-bed, 36,000-square foot medical facility is staffed by a team of internationally recognized scientists, including clinical pharmacologists and neuropsychologists, physicians, research nurses, pharmacists, paramedics and research assistants. DecisionLine employs approximately 110 full-time and 130 part-time associates. The company has grown its revenue at an average compound annual growth rate of 60 percent since 2002, and has been named to Profit magazine's list of the top 100 fastest growing companies in Canada. Dr. Sellers and Dr. Romach will play key leadership roles as part of Kendle's Early Phase organization. Dr. Sellers will serve as General Manager, Early Phase, Toronto and Senior Scientist, Kendle International and Dr. Romach will assume the role of Head of Clinical Operations and Medical Affairs, Early Phase, Toronto and Senior Scientist, Kendle International.

"We are extremely pleased to join Kendle," said Dr. Sellers, "DecisionLine's specialized experience in Phase I together with Kendle's global capabilities and footprint will provide great benefits to the customers, investors and associates of our combined organization as we work to establish Kendle as a world leader in early phase development services."

Kendle's existing early phase capabilities include a Clinica
'/>"/>

SOURCE Kendle International Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality